Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ANIK 
Anika Therapeutics Inc (ANIK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: ANIK (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $17.33
1 Year Target Price $17.33
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -3.21% | Avg. Invested days 59 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 124.72M USD | Price to earnings Ratio - | 1Y Target Price 17.33 |
Price to earnings Ratio - | 1Y Target Price 17.33 | ||
Volume (30-day avg) 3 | Beta 0.63 | 52 Weeks Range 7.87 - 25.83 | Updated Date 09/16/2025 |
52 Weeks Range 7.87 - 25.83 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.9 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -52.93% | Operating Margin (TTM) -14.81% |
Management Effectiveness
Return on Assets (TTM) -2.4% | Return on Equity (TTM) -7.23% |
Valuation
Trailing PE - | Forward PE 48.08 | Enterprise Value 96537478 | Price to Sales(TTM) 1.09 |
Enterprise Value 96537478 | Price to Sales(TTM) 1.09 | ||
Enterprise Value to Revenue 0.84 | Enterprise Value to EBITDA 175.12 | Shares Outstanding 14418100 | Shares Floating 10362570 |
Shares Outstanding 14418100 | Shares Floating 10362570 | ||
Percent Insiders 4.88 | Percent Institutions 88.9 |
Upturn AI SWOT
Anika Therapeutics Inc
Company Overview
History and Background
Anika Therapeutics Inc. was founded in 1992. It focuses on developing, manufacturing, and commercializing therapeutic products for tissue protection, healing, and repair. It has grown through internal development and strategic acquisitions, focusing on hyaluronic acid (HA)-based technologies.
Core Business Areas
- Joint Health: Development and sales of products to treat osteoarthritis pain, primarily based on hyaluronic acid (HA) injection technology, viscosupplements. Also includes regenerative solutions such as BoneFix.
- Soft Tissue Repair & Regeneration: Products focused on sports medicine soft tissue injuries and regenerative therapies, including joint preservation and tendon repair with technologies such as HYAFF and hyaluronic acid based products.
Leadership and Structure
Anika Therapeutics Inc. is led by a management team including the CEO, CFO, and heads of various departments (R&D, Sales, Marketing, Operations). The organizational structure is typical of a publicly traded company, with a board of directors overseeing the management team.
Top Products and Market Share
Key Offerings
- Monovisc: A single-injection hyaluronic acid (HA) viscosupplement for osteoarthritis (OA) knee pain. Key competitor: Durolane (Bioventus). Market share data is not publicly disclosed but it is a key revenue driver for Anika.
- Orthovisc: A multi-injection hyaluronic acid (HA) viscosupplement for osteoarthritis (OA) knee pain. Competitors include Euflexxa and Synvisc (Sanofi). Anika's Orthovisc is widely used.
- CINGAL: A single-injection HA viscosupplement combined with a steroid for rapid pain relief. Competitor: Triamcinolone Acetonide. Market share data is not publicly available, but CINGAL offers a differentiated approach.
- HYALOFAST: A biodegradable scaffold to support cartilage regeneration in damaged joints. Competitors include DeNovo NT. Market share data is not publicly available.
Market Dynamics
Industry Overview
The market for osteoarthritis treatment, soft tissue repair, and regenerative medicine is growing, driven by an aging population, increasing obesity rates, and demand for less invasive procedures. The hyaluronic acid (HA) market is a significant segment of this industry.
Positioning
Anika Therapeutics Inc. holds a strong position in the HA-based viscosupplement market, particularly for OA knee pain. It is expanding into regenerative medicine and soft tissue repair to diversify its product offerings.
Total Addressable Market (TAM)
The global hyaluronic acid market is estimated at several billion USD annually. Anika is positioned to capture a significant portion of this TAM through its existing products and pipeline of new products in regenerative solutions.
Upturn SWOT Analysis
Strengths
- Established presence in the hyaluronic acid market
- Proprietary HA-based technologies
- Diverse portfolio of products for joint health and soft tissue repair
- Strong brand recognition within target market
Weaknesses
- Reliance on HA-based products
- Competition from larger pharmaceutical companies
- Limited geographic diversification
- Vulnerability to reimbursement changes and regulatory hurdles
Opportunities
- Expansion into new geographic markets
- Development of innovative regenerative medicine products
- Strategic acquisitions to broaden product portfolio
- Increased adoption of minimally invasive procedures
Threats
- Intense competition from established players
- Pricing pressures from payers
- Potential for new technologies to disrupt the market
- Regulatory changes affecting product approval and reimbursement
Competitors and Market Share
Key Competitors
- SNY
- BONT
Competitive Landscape
Anika competes with both large pharmaceutical companies (SNY) and specialized orthopedic companies (BONT). Anika's competitive advantage lies in its specialized HA-based technology and focus on specific therapeutic areas, but it faces challenges from larger companies with greater resources.
Major Acquisitions
Parcus Medical
- Year: 2019
- Acquisition Price (USD millions): 35
- Strategic Rationale: Expanded Anika's sports medicine portfolio with innovative soft tissue fixation products.
Growth Trajectory and Initiatives
Historical Growth: Historical growth needs to be replaced by the real current numerical data.
Future Projections: Future projections needs to be replaced by the real current numerical data.
Recent Initiatives: Recent initiatives include new product launches, strategic acquisitions, and partnerships to expand into new markets and technologies.
Summary
Anika Therapeutics is a specialized company with a strong presence in the HA market, particularly for joint health. Its focus on HA-based technologies provides a competitive advantage, but its smaller size compared to major pharmaceutical companies creates challenges. Anika must continue to innovate and diversify to maintain its growth trajectory. It should look out for pricing pressures and regulatory hurdles.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data and analyst estimates are subject to change. Past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Anika Therapeutics Inc
Exchange NASDAQ | Headquaters Bedford, MA, United States | ||
IPO Launch date 1993-04-29 | President, CEO & Director Dr. Cheryl Renee Blanchard Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 288 | Website https://www.anika.com |
Full time employees 288 | Website https://www.anika.com | ||
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products include Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide short-and long-term pain relief. The company's joint preservation and restoration product family comprises orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions. In addition, the company offers non-orthopedic products comprising HA-based products for Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier for use after abdominal-pelvic surgeries; and Hyalomatrix for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.